Verve Therapeutics Company Insiders

VERV Stock  USD 6.58  0.30  4.36%   
Verve Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Verve Therapeutics suggests that vertually all insiders are panicking. Verve Therapeutics employs about 255 people. The company is managed by 11 executives with a total tenure of roughly 595 years, averaging almost 54.0 years of service per executive, having 23.18 employees per reported executive.

Verve Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-04-02Joan NickersonDisposed 1514 @ 8.24View
2023-11-29Allison DorvalDisposed 554 @ 11.45View
Monitoring Verve Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verve Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Verve Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1948) % which means that it has lost $0.1948 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3478) %, meaning that it created substantial loss on money invested by shareholders. Verve Therapeutics' management efficiency ratios could be used to measure how well Verve Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. At this time, Verve Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 120.5 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 1.4 M in 2024.
Common Stock Shares Outstanding is likely to drop to about 57.9 M in 2024. Net Loss is likely to climb to about (134.6 M) in 2024

Verve Therapeutics Workforce Comparison

Verve Therapeutics is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 4,542. Verve Therapeutics holds roughly 255 in number of employees claiming about 6% of equities under Health Care industry.

Verve Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verve Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verve Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Verve Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
0.5
1
2
 3,315 
 4,829 
2023-12-01
1.0
2
2
 1,801,875 
 2,429 
2023-03-01
1.0
5
5
 1,105,600 
 237,446 
2022-12-01
0.0548
4
73
 97,875 
 1,358,338 
2022-09-01
0.5
5
10
 292,000 
 442,978 
2022-06-01
3.6667
11
3
 196,000 
 53,219 
2022-03-01
0.7
7
10
 717,544 
 215,311 
2021-12-01
0.5294
9
17
 326,893 
 355,386 
2021-06-01
0.7091
39
55
 38,133,355 
 298,279,171 

Verve Therapeutics Notable Stakeholders

A Verve Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Verve Therapeutics often face trade-offs trying to please all of them. Verve Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Verve Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Burt MDCoFounder BoardProfile
Andrew JDCOO PresidentProfile
Joan MBAChief OfficerProfile
FACC MDCoFounderProfile
Anthony MDCoFounder MemberProfile
Allison DorvalCFO OfficerProfile
Andrew MDChief OfficerProfile
Sekar MDCEO CoFounderProfile
Margaret BeaudoinVP FinProfile
Issi MBACoFounder AdvisorProfile
MD MPHCoFounder AdvisorProfile

About Verve Therapeutics Management Performance

The success or failure of an entity such as Verve Therapeutics often depends on how effective the management is. Verve Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Verve management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Verve management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.27)(0.28)
Return On Capital Employed(0.31)(0.33)
Return On Assets(0.27)(0.28)
Return On Equity(0.33)(0.32)
The data published in Verve Therapeutics' official financial statements usually reflect Verve Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Verve Therapeutics. For example, before you start analyzing numbers published by Verve accountants, it's critical to develop an understanding of what Verve Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Verve Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verve Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Verve Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Verve Therapeutics. Please utilize our Beneish M Score to check the likelihood of Verve Therapeutics' management manipulating its earnings.

Verve Therapeutics Workforce Analysis

Traditionally, organizations such as Verve Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Verve Therapeutics within its industry.

Verve Therapeutics Manpower Efficiency

Return on Verve Therapeutics Manpower

Revenue Per Employee46.1K
Revenue Per Executive1.1M
Net Loss Per Employee784.6K
Net Loss Per Executive18.2M
Working Capital Per Employee2.4M
Working Capital Per Executive54.6M
When determining whether Verve Therapeutics is a strong investment it is important to analyze Verve Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Verve Therapeutics' future performance. For an informed investment choice regarding Verve Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verve Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Verve Stock analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is Verve Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verve Therapeutics. If investors know Verve will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verve Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.12)
Revenue Per Share
0.183
Quarterly Revenue Growth
4.083
Return On Assets
(0.19)
Return On Equity
(0.35)
The market value of Verve Therapeutics is measured differently than its book value, which is the value of Verve that is recorded on the company's balance sheet. Investors also form their own opinion of Verve Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Verve Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verve Therapeutics' market value can be influenced by many factors that don't directly affect Verve Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verve Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verve Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verve Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.